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Objectives: The use of prophylactic antibiotics in severe acute pancreatitis (SAP) is controversial. The
aim of this study was to compare the effects of antibiotics administered as prophylaxis and as treatment
on demand, respectively, in two prospective, non-randomized cohorts of patients.
Methods: The study population consisted of 210 patients treated for SAP. In Group 1 (n = 103), patients
received prophylactic antibiotics (ciprofloxacin, metronidazole). In Group 2 (n = 107), patients were treated
on demand. Ultrasound-guided drainage and/or surgical debridement of infected necrosis were per-
formed when the presence of infected pancreatic necrosis was demonstrated. The primary endpoints
were infectious complication rate, need for and timing of surgical interventions, incidence of nosocomial
infections and mortality rate.
Results: Ultrasound-guided fine needle aspiration [in 18 (16.8%) vs. 13 (12.6%) patients; P = 0.714],
ultrasound-guided drainage [in 15 (14.0%) vs. six (5.8%) patients; P = 0.065] and open surgical necro-
sectomy [in 10 (9.3%) vs. five (4.9%) patients; P = 0.206] were performed more frequently and earlier [at
16.6  7.8 days vs. 17.2  6.7 days (P = 0.723); at 19.5  9.4 days vs. 24.5  14.2 days (P = 0.498), and
at 22.6  13.5 days vs. 26.7  18.1 days (P = 0.826), respectively] in Group 2 compared with Group 1.
There were no significant differences between groups in mortality and duration of stay in the surgical ward
or intensive care unit.
Conclusions: The results of this study support the suggestion that the use of prophylactic antibiotics
does not affect mortality rate, but may decrease the need for interventional and surgical management,
and lower the number of reoperations.
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Introduction
Annual incidences of acute pancreatitis (AP) are reported to range
from five to 80 cases per 100 000 population.1–3 This wide varia-
tion in incidence reflects several factors, including: population
differences; dominant aetiology (alcohol abuse, biliary stone
disease, etc.), and variations in clinical assessment.3,4 Overall mor-
tality rates are between 10% and 20% and can reach 50% in
patients with severe acute necrotizing pancreatitis.5,6 Persistent
organ failure and uncontrolled systemic inflammatory response
syndrome are associated with the highest mortality rates during
the first weeks of the disease.6,7 Secondary pancreatic infection,
which usually develops from the third week after the onset of AP,
may affect up to 40–70% of patients with pancreatic necrosis
exceeding 30%.7–9
In most patients, bacteria complicating acute necrotizing pan-
creatitis originate from the gastrointestinal tract and include
Escherichia coli, Proteus mirabilis, Enterococcus faecalis, Pseudo-
monas aeruginosa, Bacteroides spp. and Clostridium spp.10,11
Some recent research has reported a rising incidence of fungal
infection (Candida spp.) of up to 35%.12 Despite some clinical and
experimental studies, the pathogenesis of secondary infection
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of the necrotic pancreas remains unclear; however, some evidence
supports the hypothesis that such infection represents the trans-
location of a microorganism from the gastrointestinal tract.10,13,14
Haematogenous dissemination, ascending infection caused by
reflux into the pancreatic duct, the migration of microorganisms
via the lymphatic system or a combination of these factors are the
likely point of entry.15,16
The prophylactic use of antibiotics to reduce the rate of
secondary infection of pancreatic tissue, systemic infectious
complications and mortality rates remains controversial.16–18
Broad-spectrum antibiotics that achieve a minimum inhibitory
concentration (MIC) in necrotic pancreatic tissue are needed if
antibiotics are to be successful in clinical practice.7,12,19
A number of experimental and clinical studies evaluating the
benefit of antimicrobial prophylaxis to prevent secondary infec-
tion of pancreatic necrosis have been published within the last
decade.17,18,20–27 However, there is still no unanimous agreement as
to whether prophylactic antibiotics should be used routinely. The
aim of this study was to compare the effects of antibiotic prophy-
laxis with the effects of antibiotic treatment administered on
demand in two prospective, non-randomized cohorts of patients.
Materials and methods
Study design and patient population
This was a prospective, non-randomized, single-centre, cohort
study. The study was approved by the regional ethics committee.
All patients provided written informed consent. Prospective data
collection was performed at the Department of Surgery, Lithua-
nian University of Health Sciences using a specially developed and
maintained database from 1 January 2005 to 1 March 2010. All
patients admitted to the Department of Surgery or transferred
from other institutions with predicted severe and/or necrotizing
severe acute pancreatitis (SAP) for which the onset of disease
occurred within the previous 72 h were eligible for inclusion in
the study (n = 210). The diagnosis of SAP was based on clinical
symptoms (abdominal pain, nausea and vomiting), elevation of
serum a-amylase greater than three times the normal level, and
either or both of the following characteristics: C-reactive protein
(CRP) of > 120 mg/l, and a clinical picture of SAP as demon-
strated by an APACHE II (acute physiology and chronic health
evaluation II) score of > 7. The presence of pancreatic necrosis was
confirmed and its volume assessed by contrast-enhanced com-
puted tomography (CT) performed at 5–7 days after the onset of
disease, even if CT had been performed on admission. Two dif-
ferent scoring systems were consistently employed to assess the
severity of AP on admission and during follow-up: APACHE II,
and MODS (multiple organ dysfunction syndrome).
The study timeframe was divided into two distinct periods,
characterized by the different treatment strategies utilized in each.
A total of 103 patients (Group 1), admitted to the surgical ward
from 1 January 2005 to 31 January 2007, were routinely given
antibiotic prophylaxis (ciprofloxacin 800 mg/day, metronidazole
1500 mg/day for 14 days) if at least one of the following indica-
tions was present within the first 72 h from the onset of disease:
CRP > 120 mg/l; APACHE II score > 7, and/or necrosis of > 30%
as demonstrated on contrast-enhanced CT.
During the period from 1 January 2008 to 31 December 2009, a
total of 107 patients (Group 2), admitted to the surgical ward
based on the same criteria, received no prophylactic antibiotic
treatment because meta-analyses published in the period from
2003 to 2008 demonstrated no clear benefit of antibiotic
prophylaxis in the management of SAP.14,18,28 Instead, patients
in this group were treated on demand with i.v. antibiotics
according to bacterial culture results.
Patients treated during the period from 1 February 2007 to
31 December 2007 were deliberately excluded from the statisti-
cal analysis because this was a transitional period during which
the follow-up and management protocol of patients with AP
remained essentially the same as those applied during the period
from 1 January 2005 to 31 January 2007, but antibiotic prophy-
laxis was gradually withdrawn from routine clinical practice. The
only change to the former protocol other than that to antibiotic
prophylaxis was that patients diagnosed with SAP were routinely
monitored for intra-abdominal pressure (IAP) starting from May
2007. At that time, a study had been initiated to assess the value of
widely used clinical scores in the early identification of AP patients
who were likely to suffer from intra-abdominal hypertension
(IAH) and abdominal compartment syndrome (ACS).29 In the
context of this study, the feasibility and effectiveness of subcuta-
neous fasciotomy of the anterior rectus abdominis sheath were
assessed, as well as the role of ultrasound (US)-guided drainage of
intra-abdominal and peripancreatic fluid collections in the man-
agement of ACS.30 However, Group 1 patients were not routinely
monitored for elevated IAP.
All patients included in the current study were continuously
monitored until discharge. A septic condition or extrapancreatic
organ failure were considered as indications to obtain bacterial
cultures from peripancreatic fluid collections, blood, urine,
sputum and/or tracheal aspirate. Ultrasound-guided fine needle
aspiration (FNA) was performed in all patients in whom pancre-
atic necrosis had been confirmed by CT and in whom persisting
symptoms of SAP (APACHE II score > 7 or failure of at least one
extrapancreatic organ) and/or signs of sepsis (usually not earlier
than week 2 after the onset of disease) were apparent. When
infection was demonstrated, US-guided drainage, or retroperito-
neoscopic or surgical debridement of infected necrosis was
performed. A minimally invasive step-up approach was used
throughout the entire study period. Percutaneous drainage was
performed in all patients as a first step, whereas retroperitoneo-
scopic or open surgical debridement (depending on the size and
accessibility of the infected collection) was reserved only for
patients in whom no improvement was seen after percutaneous
drainage. A septic condition (sepsis) in the current study was
defined as acute organ dysfunction secondary to infection and/or
septic shock (severe sepsis plus hypotension not reversed with
fluid resuscitation).
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Patients with chronic pancreatitis and patients with AP referred
from other institutions at > 72 h after the onset of disease were
excluded from this study.
Multidrug-resistant organisms (MDROs) were defined as
pathogens, predominantly bacteria, that were resistant to one or
more classes of antimicrobial agents. In particular, these included
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococci (VRE) and certain Gram-negative bacteria
(GNB) producing extended-spectrum b-lactamases (ESBLs), and
others that were resistant to multiple classes of antimicrobial
agents.
Statistical analysis
Statistical analysis was performed using spss Version 14.0 for
Windows (SPSS, Inc., Chicago, IL, USA). Data are presented as the
mean  standard deviation (SD) (for normally distributed data)
or as the median and range. For comparisons between groups,
Student’s t-test (for normally distributed data) or Mann–Whitney
test were employed as appropriate. A P-value of < 0.05 was con-
sidered to indicate statistical significance. The power analysis for
the study was performed based on previously reported rates of the
primary outcomes (e.g. rates of image-guided drainage and sur-
gical debridement) with a = 0.05 and an estimated sample size of
100 patients in each arm, and was estimated to be > 0.8.
Results
Patient demographics and the aetiology of pancreatitis by group
are shown in Table 1.
In Group 1, all patients were administered with prophylactic
antibiotics and 60 (58.3%) patients remained on antibiotics for
> 14 days. In Group 2, antibiotics were administered to only 20
patients (18.7%). Multidrug-resistant microorganisms, requiring
the administration of carbapenems, were identified more fre-
quently in Group 1 [in eight patients (7.8%)] compared with
Group 2 [in five patients (4.7%)]; however, the difference was not
statistically significant (P = 0.519).
Ultrasound-guided FNA, US-guided drainage and open surgi-
cal necrosectomy were performed more frequently and earlier in
Group 2 than in Group 1, although the differences did not reach
statistical significance (Table 2). Positive cultures from first FNA
samples were obtained in nine patients in Group 2 and seven
patients in Group 1 (P = 0.796). Repeated FNA (two or more
procedures) was performed in six patients in Group 2 and five
patients in Group 1 (P = 0.712). Overall, surgical interventions
(open necrosectomy, repeated surgery and debridement) were
more frequently performed in Group 2 (P = 0.016). The timing of
surgical debridement did not differ statistically between the
groups (Table 2).
In nine patients in Group 2, FNA and/or US-guided drainage of
large intra-abdominal fluid collections were performed in the
course of the first week to relieve ACS. Furthermore, a subcuta-
neous anterior m. rectus fasciotomy was performed in one patient
in Group 2 during the first week of disease in response to multiple
organ dysfunction and ACS when conservative and interventional
management had failed. However, these interventions were not
included in the final statistical analysis because patients in Group
1 were not routinely monitored for elevated IAP and presence of
ACS (only one patient was identified as having ACS in Group
1 and a subcutaneous anterior m. rectus fasciotomy was
performed).
The main clinical outcomes are shown in Table 3.
Bacterial and fungal culture analyses are shown in Table 4.
However, there was no statistically significant difference between
the treatment groups in the prevalence of MDROs (Table 5).
Subgroup analysis of patients with necrotizing AP (49 patients
in Group 1 and 65 patients in Group 2) revealed no statistically
significant differences in terms of the main outcomes, such
Table 1 Demographic data for patients and characteristics of acute pancreatitis
Characteristic Group 1 (n = 103) Group 2 (n = 107) Whole sample (n = 210) P-value
Age, years, mean  SD 54  16 51  18 53  17 0.424
Gender, n (%)
Male 54 (52.4%) 60 (56.1%) 114 (54.3%) 0.678
Female 49 (47.6%) 47 (43.9%) 96 (45.7%) –
Aetiology of acute pancreatitis, n (%)
Alcohol (ethanol) 44 (42.7%) 39 (36.4%) 83 (39.5%) 0.434
Biliary 54 (52.4%) 66 (61.7%) 120 (57.2%) –
Idiopathic 5 (4.9%) 2 (1.9%) 7 (3.3%) –
Severity of acute pancreatitis
APACHE II score, mean  SD 7  5 7  4 7  5 0.811
MODS score, mean  SD 3  3 2  2 2  2 0.141
Necrosis  30%, n (%) 49 (47.6%) 65 (60.7%) 114 (54.3%) 0.072
Total 103 (100%) 107 (100%) 210 (100%)
SD, standard deviation; APACHE II, acute physiology and chronic health evaluation II; MODS, multiple organ dysfunction syndrome.
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as sepsis, infected pancreatic necrosis, contiguous infections
(infections of the urinary or respiratory tracts), MODS, mortality
rate, and interventional or surgical management. Potentially, this
may be explained by the overlap of subgroups presenting with
organ failure and/or sepsis and necrotizing AP (31/40 patients in
Group 1 and 32/40 patients in Group 2 presenting with severe
multiple organ failure and/or sepsis also had pancreatic necrosis
of  30%).
Discussion
Antibiotic prophylaxis in SAP (presenting with pancreatic necro-
sis, organ failure and/or sepsis) has been a subject of controversy
over the last two decades. Numerous clinical trials have been per-
formed, with somewhat contradictory results.24,31–38 The aim of
the current study was to compare the effects of antibiotic prophy-
laxis and treatment on demand, respectively, in two sequential
non-randomized cohorts of patients.
The results of the current study showed that the use of pro-
phylactic antibiotics (Group 1) (ciprofloxacin, metronidazole)
had no significant positive effect on primary endpoints, such as
the incidence of infectious complications and overall mortality
rate, compared with treatment on demand (Group 2). However,
prophylactic antibiotic management in SAP seems to have some
indirect positive effects in that it may lower the number of
image-guided and surgical interventions (percutaneous drainage,
necrosectomy, repeated debridement) required, without increas-
ing the risk for occurrence of nosocomial and multidrug-
resistant infections. Although the latter factors had no significant
direct effects on patient survival and/or morbidity, repeated
surgery undoubtedly causes an additional burden to the patient
and is associated with increased postoperative morbidity and
additional treatment costs;39,40 therefore this phenomenon should
be examined in further dedicated trials. Whether these differ-
ences related to better local infection control in the antibiotic
prophylaxis group or a sense of insecurity about the ‘wait and
Table 2 Interventional procedures
Interventional procedure Group 1 (n = 103) Group 2 (n = 107)a Whole sample (n = 210) P-valueb
Ultrasound-guided FNA, n (%) 13 (12.6%) 18 (16.8%) 31 (14.8%) 0.714
Day, mean  SD 17  7 7  8 17  7 0.723
Ultrasound-guided drainage, n (%) 6 (5.8%) 15 (14.0%) 21 (10.0%) 0.065
Day, mean  SD 25  14 20  9 21  11 0.498
Necrosectomy, n (%) 5 (4.9%) 10 (9.3%) 15 (7.1%) 0.206
Day, mean  SD 27  18 23  13 24  15 0.826
All surgical interventionsc 8 (7.6%) 21 (19.6%) 29 (13.8%) 0.016
aPatients with increased intra-abdominal pressure were excluded (FNA and drainage were performed in the course of the first week after the onset
of disease).
bValues shown in bold indicate statistical significance at P < 0.05.
cAll surgical interventions = open necrosectomy, fasciotomy, repeated surgery.
SD, standard deviation; FNA, fine needle aspiration.
Table 3 Clinical outcomes
Clinical outcomes Group 1 (n = 103) Group 2 (n = 107) Whole sample (n = 210) P-value
Outcomes, n (%)
Sepsis 6 (5.8%) 7 (6.5%) 13 (6.2%) 1.000
Contiguous infections 13 (12.6%) 12 (11.2%) 25 (11.9%) 0.833
Infected pancreatic necrosis 9 (8.7%) 7 (6.5%) 16 (7.6%) 0.796
Major organ failurea 17 (16.5%) 13 (12.1%) 30 (14.3%) 0.432
Severe acute pancreatitis 40 (38.8%) 47 (43.9%) 87 (41.4%) 0.486
Need for ICU stay 29 (28.2%) 27 (25.2%) 56 (26.7%) 0.643
Length of stay, days, mean  SD
Surgical ward 14  12 11  11 13  12 0.244
Intensive care unit 2  7 3  10 3  9 0.148
Deaths, n (%)
Overall deaths 13 (12.6%) 21 (19.6%) 34 (16.2%) 0.192
Early deathsb 9 (8.7%) 12 (11.2%) 21 (10.0%) 0.306
aMajor organ failure represents the failure of two or more organ systems.
bEarly deaths represent deaths in the course of the first week after the onset of disease.
ICU, intensive care unit; SD, standard deviation.
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see’ strategy adopted in the context of worsening health status in
patients in the treatment-on-demand group remains debatable.
However, the lower rate of surgical interventions and the absence
of any obvious association of antibiotic prophylaxis with noso-
comial infection in the current study at least indirectly support
the use of antibiotic prophylaxis in SAP, which is in accord
with the recently published recommendations of an expert panel
on the management of AP.41
Table 4 Bacterial culture analysis
Bacterial culture Group 1 (n = 103) Group 2 (n = 107) P-valuea
All, n 299 199
Positive, n (%) 145 (48.5%) 95 (47.7%) 0.686
Microorganisms, n 103 132 0.001
Enterobacteriaceae, n (%) 31 (30.1%) 69 (52.3%) 0.029
Escherichia coli 14 (13.6%) 26 (19.7%) 0.387
Citrobacter spp. 6 (5.8%) 2 (1.5%) 0.145
Proteus spp. 1 (0.9%) 8 (6.1%) 0.278
Klebsiella spp. 7 (6.8%) 21 (15.9%) 0.643
Enterobacter spp. 2 (1.9%) 5 (3.8%) 1.000
Other 1 (0.9%) 7 (5.3%) 0.432
Enterococcaceae, n (%) 17 (16.5%) 15 (11.4%) 0.707
Staphylococcaceae, n (%) 6 (5.8%) 18 (13.6%) 0.046
Staphylococcus aureus 1 (0.9%) 8 (6.1%) 0.224
Coagulase-negative staphylococci 3 (2.9%) 10 (7.6%) 0.813
Other 2 (1.9%) 0 0.011
Streptococcaceae, n (%) 3 (2.9%) 1 (0.8%) 0.205
Candida spp., n (%) 11 (10.7%) 5 (3.8%) 0.043
Corynebacterium spp., n (%) 11 (10.7%) 1 (0.8%) 0.002
Pseudomonas spp. + Acinetobacter spp., n (%) 17 (16.5%) 14 (10.6%) 0.175
Other, n (%) 7 (6.8%) 9 (6.8%) 0.995
aValues shown in bold indicate statistical significance at P < 0.05.
Table 5 Antibiotic-resistant strands
Bacterial culture analysis Group 1 (n = 103) Group 2 (n = 107) P-value
Enterobacteriaceae (cefotaxim) 15 (48.4%) 26 (37.7%) 0.314
Escherichia coli 5 (35.7%) 3 (11.5%) 0.376
Citrobacter spp. 3 (50.0%) 0 0.673
Proteus spp. 1 (100%) 1 (12.5%) 0.478
Klebsiella spp. 4 (57.0%) 17 (80.0%) 0.499
Enterobacter spp. 2 (100%) 2 (40.0%) 0.546
Other 0 3 (42.9%) 0.408
Enterococcaceae (penicillin) 7 (41.2%) 8 (53.3%) 0.739
Staphylococcaceae (oxacillin) 4 (66.7%) 10 (55.5%) 0.633
Staphylococcus aureus 0 5 (62.5%) 0.906
Coagulase-negative staphylococci 2 (66.7%) 5 (50.0%) 0.612
Other 2 (100%) 0 0.242
Streptococcaceae (penicillin) 0 0 0.540
Candida spp. 1 (9.1%) 0 0.486
Corynebacterium spp. (cefuroxim) 9 (81.8%) 1 (100%) 0.389
Pseudomonas spp. + Acinetobacter spp. (meropenem) 3 (17.6%) 2 (14.2%) 0.800
Table represents number and percentage of antibiotic resistant bacteria in each particular family and or species of bacteria, i.e. E. coli identified in
Group 1 in 15 cases, and in 5 cases it was an antibiotic resistant strand (35.7%).
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After analysing bacteriology in SAP,Noor et al.42 concluded that
E. coli (Enterobacteriaceae) was the most common organism in
SAP. The antibiotic sensitivity pattern showed that most of the
bacteria were sensitive to b-lactam antibiotics, aminoglycosides
and imipenem.
Bassi et al.43 reported amulticentre trial comparing the effects of
pefloxacin with those of imipenem in the treatment of acute
necrotizing pancreatitis (n = 60). The trial revealed a theoretical
benefit with imipenem, although mortality rates did not differ
significantly between the two groups.43 In a multicentre study,
Isenmann et al.37 showed that prophylactic antibiotic treatment
(ciprofloxacin 400 mg b.i.d. combinedwithmetronidazole 500 mg
b.i.d.) did not significantly reduce the incidence of infected pan-
creatic necrosis. Similar results were obtained in the current study,
in which incidences of infected pancreatic necrosis were deter-
mined as 8.4% in Group 1 and 6.8% in Group 2 (P > 0.05).
In 2009 Garcia-Barrasa et al.23 published the results of a double-
blind, placebo-controlled trial, which demonstrated that the pro-
phylactic use of ciprofloxacin in patients with severe necrotizing
pancreatitis reduced neither the risk for secondary pancreatic
infection nor the mortality rate. However, the small number of
patients (n = 41) included in this study should be considered a
serious drawback to the conclusiveness of this negative result.
A meta-analysis of nine randomized trials, analysing the effects
of prophylactic antibiotics in acute necrotizing pancreatitis, was
published by Yao et al.44 in 2010. It showed that prophylactic anti-
biotics reduced the occurrence of infected pancreatic necrosis (in
the single-centre trials subgroup), but did not affect mortality
rate, occurrence of non-pancreatic infection or need for surgical
intervention.44 Similarly, the current study showed no beneficial
results of prophylactic antibiotics in terms of the prevalence of
infected pancreatic necrosis, length of hospital stay (13.71 12.15
days vs. 11.43  11.16 days) or mortality (12.6% vs. 19.6%).
Other meta-analyses have shown contradictory results. A
meta-analysis of five trials, by Mazaki et al.,45 found no positive
effect of prophylactic antibiotics. However, another meta-analysis
of eight trials, by Xue et al.,34 showed that prophylactic antibiot-
ics were associated with a significant reduction in pancreatic,
peripancreatic and non-pancreatic infection, and in length of
hospital stay, but were not beneficial in reducing mortality rate
and need for surgical intervention. Seven trials were included in
a meta-analysis published in 2008.28 This study suggested that
prophylactic i.v. antibiotics did not reduce infected pancreatic
necrosis or mortality.
In a recently updated Cochrane Database review of seven
studies, Villatoro et al.46 found no benefit of antibiotics in
preventing infection of pancreatic necrosis or mortality, except
when imipenem (a b-lactam) was considered in isolation, when a
significant decrease in pancreatic infection was found. The
authors noted that none of the studies included in the review
were adequately powered and further better designed studies
are needed if the use of antibiotic prophylaxis is to be
recommended.46
In conclusion, whether or not prophylactic antibiotics are
effective in preventing infection in SAP remains controversial. A
panel of experts recently provided a Level A recommendation
regarding the use of prophylactic broad-spectrum antibiotics in
CT-proven necrotizing pancreatitis.41 The current data support
this recommendation as this strategy decreases the need for inter-
ventional and surgical management, and reduces the frequency of
reoperation, although it does not affect the rate of mortality.
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